English  |  正體中文  |  简体中文  |  Total items :2823489  
Visitors :  30354628    Online Users :  887
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"謝明彥"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 51-75 of 97  (4 Page(s) Totally)
<< < 1 2 3 4 > >>
View [10|25|50] records per page

Institution Date Title Author
高雄醫學大學 2007 The HBV Infection Among Aboriginal Children 20 Years After Immunization In Taiwan  莊萬龍;余明隆;戴嘉言;何啟功;黃釧峰;侯乃仁;李立柏;謝明彥;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇 
高雄醫學大學 2007 HEPATIC SPLENOSIS – TWO CASES REPORT  葉明倫;王良彥;黃駿逸;謝明彥;陳信成;林子堯;莊萬龍;張文燦;李金德;蔡志仁;劉金昌 
高雄醫學大學 2007 干安能治療B型肝炎引起失償非肝硬化病患早期死亡率及反應-以MELD及INDEX指標評估  戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 
高雄醫學大學 2007 The antinuclear antibody is associated with lower RNA levels of hepatitis C virus and more advanced fibrosis in chronic hepatitis C patients  謝明彥;黃志富;侯乃仁;戴嘉言;李立柏;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍;余明隆 
高雄醫學大學 2007 Almost all HCV G2 Pts With Rapid Virologic Response at Wk 4 Achieve a SVR With 16 Wks of Treatment  余明隆;戴嘉言;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 
高雄醫學大學 2007 Outcome of chronic hepatitis C patients who required early termination of peginterferon-alfa plus ribavirin combination therapy  余明隆;戴嘉言;謝明彥;黃志富;張文宇;莊萬龍 
高雄醫學大學 2007 Evaluation of the Abbott HCV RealTime PCR Assay for quantification of HCV viral loads  莊萬龍;黃志富;余明隆;戴嘉言;李立柏;謝明彥;林子堯;陳信成;謝明裕;張文宇 
高雄醫學大學 2007 Human leukocyte antigen class I and II alleles and response to peginterferon plus ribavirin combination therapy in chronic hepatitis C patients  莊萬龍;戴嘉言;謝明彥;黃志富;張文宇;余明隆 
高雄醫學大學 2007 Different Features In Liver Histopathology Of HCV Monoinfection And HCV/HBV Dual Infection  李立柏;余明隆;戴嘉言;侯乃仁;謝明彥;林子堯;陳信成;謝明裕;王良彥;Chen, Tong-Jong;張文宇;莊萬龍 
高雄醫學大學 2007 The Seroprevalence Of HBV And HCV Infection In Southern Taiwan- Large Scale Community-Based Study  莊萬龍;余明隆;戴嘉言;林嘉益;侯乃仁;李立柏;謝明彥;黃志富;謝明裕;張文宇 
高雄醫學大學 2007 Transforming Growth Factor-Beta 1 Gene Polymorphisms In High Dose IFN/Ribavirin treated CHC Patients  戴嘉言;余明隆;張文宇;李立柏;潘文正;侯乃仁;謝明彥;黃志富;陳信成;林子堯;謝明裕;王良彥;莊萬龍 
高雄醫學大學 2007 Early Mortality And Responses In Non-Cirrhotic Decompensated CHB Patients With Lamivudine Therapy  戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;陳信成;王良彥;張文宇;莊萬龍 
高雄醫學大學 2007 EARLY MORTALITY AND RESPONSES IN NON-CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B-RELATED DECOMPENSATION WITH LAMIVUDINE THERAPY: EVALUATION OF MELD AND INDEX SCORING SYSTEMS AS PROGNOSTIC PREDICTORS  戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 
高雄醫學大學 2007 The presence of Antinuclear Antibody is associated with a negative response to combination therapy with peginterferon and ribavirin for patients without genotype 1 chronic hepatitis C infection  謝明彥;戴嘉言;黃志富;莊萬龍;侯乃仁;李立柏;陳信成;謝明裕;王良彥;張文宇;余明隆 
高雄醫學大學 2007 High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 wks with pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): Prospective, randomized, controlled study comparing 24 & 48 wks of treatm  余明隆;戴嘉言;黃志富;李立柏;謝明彥;丘長富;侯乃仁;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍* 
高雄醫學大學 2007 PHARMACOGENOMICS STUDY FOR 24 VS. 48 WEEKS TREATMENT OF PEGINTERFERON PLUS RIBAVIRIN FOR GENOTYPE 1b CHRONIC HEPATITIS C  戴嘉言;黃志富;謝明彥;陳信成;余明隆;莊萬龍 
高雄醫學大學 2007 RELATIONSHIP BETWEEN GLUCOSE ABNORMALITIES AND RESPONSE TO PEGYLATED INTERFERON ALFA PLUS RIBAVIRIN COMBINATION THERAPY IN CHRONIC HEPATITIS C PATIENTS  謝明彥;戴嘉言;黃志富;林子堯;余明隆;莊萬龍 
高雄醫學大學 2007 葡萄糖異常與慢性C型肝炎患者接受長效型干擾素(pegylated interferon alfa)合併ribavirin治療反應之關聯性研究  謝明彥;戴嘉言;李立柏;余明隆;王良彥;莊萬龍;張文宇 
高雄醫學大學 2006 A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.  余明隆;戴嘉言;林子堯;李立柏;侯乃仁;謝明彥;陳信成;謝明裕;王良彥;張文宇;莊萬龍 ; Ming-Lung Yu;Chia-Yen Dai;Zu-Yau Lin;Li-Po Lee;Nei-Jen Hou;Ming-Yen Hsieh;Shinn-Cherng Chen;Ming-Yuh Hsieh;Liang-Yen Wang;Wen-Yu Chang;Wan-Long Chuang 
高雄醫學大學 2006 Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.  余明隆;戴嘉言;李立柏;謝明彥;侯乃仁;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 ; Yu ML;Dai CY;Lee LP;Hsieh MY;Hou NJ;Huang JF;Lin ZY;Chen SC;Hsieh MY;Wang LY;Chang WY;Chuang WL 
高雄醫學大學 2006 Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.  戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;黃志富;謝明裕;王良彥;余明隆 ; Dai CY;Chuang WL;Chang WY;Chen SC;Lee LP;Hsieh MY;Hou NJ;Lin ZY;Huang JF;Hsieh MY;Wang LY;Yu ML 
高雄醫學大學 2006 SEN and hepatitis virus infections in nontransfused children and pediatric thalassemia patients with multiple transfusions in Taiwan  邱世欣;黃志富;張泰琮;謝明彥;戴嘉言;張文宇;莊萬龍 ; Chiou, SS;Huang, JF;Chang, TT;Hsieh, MY;Dai, CY;Yu, ML;Chang, WY;WL , Chuang
高雄醫學大學 2006 A randomized study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C  余明隆;戴嘉言;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 
高雄醫學大學 2006 Predictors for early mortality in lamivudine-treated patients with chronic hepatitis B-related decompensation in Taiwan ”has been accepted for poster presentation at the forthcoming.  戴嘉言;莊萬龍;李立柏;謝明裕;侯乃仁;陳信成;林子堯;謝明彥;王良彥;黃志富;張文宇;余明隆 
高雄醫學大學 2006 A randomized, controlled, open-label study of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 vs. 24 weeks in patients with genotype 2 hepatitis C infection  余明隆;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明彥;王良彥;張文宇;莊萬龍 

Showing items 51-75 of 97  (4 Page(s) Totally)
<< < 1 2 3 4 > >>
View [10|25|50] records per page